News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ablynx (ABLYF) Release: Publication In Accordance With Article 14 Of The Belgian Law Of 2 May 2007 Regarding The Publication Of Major Shareholdings (The "Transparency Law")



5/20/2014 11:56:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GHENT, Belgium, May 20, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Biotech Value Fund Partners LP and Biotech Value Fund Inc.

Biotech Value Fund Partners LP and Biotech Value Fund Inc notified that they have dropped below the 5% threshold (from 5.23% to 4.93%) and now hold 2,417,991 Ablynx shares of the current 49,083,327 outstanding shares of Ablynx.

Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(R), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has more than 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin MosesCEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses@ablynx.com

Marieke VermeerschAssociate Director Investor Relationst: +32 (0)9 262 00 82m: +32 (0)479 49 06 03e: marieke.vermeersch@ablynx.comFollow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Nevillet: +44 203 709 5700e: ablynx@consilium-comms.com

pdf version of the press release http://hugin.info/137912/R/1787358/613665.pdf

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Ablynx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES